All results
2 results for randomized multicenter double blind placebo controlled parallel group phase 3 study
-
Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome (AEGIS-II)
This is a phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of CSL112 on reducing…
- Ages
- 18 Years - N/A
- Sexes
- All
-
IMPALA-2
160 subjects with autoimmune pulmonary alveolar proteinosis (aPAP) will be randomized to receive once daily treatment with inhaled molgramostim or placebo for…
- Ages
- 18 Years - N/A
- Sexes
- All